Abstract:The aim of this study was to investigate the plasma proteome in individuals with intracranial aneurysms (IAs) and identify biomarkers associated with the formation and rupture of IAs. Proteomic profiles ( N = 1069 proteins) were assayed in plasma ( N = 120) collected from patients with ruptured and unruptured intracranial aneurysms (RIA and UIA), traumatic subarachnoid hemorrhage (tSAH), and healthy controls (HC) using tandem mass tag (TMT) labeling quantitative proteomics analysis. Gene ontology (GO) and pathway analysis revealed that these relevant proteins were involved in immune response and extracellular matrix organization pathways. Seven candidate biomarkers were verified by ELISA in a completely separate cohort for validation ( N = 90). Among them, FN1, PON1, and SERPINA1 can be utilized as diagnosis biomarkers of IA, with a combined area under the ROC curve of 0.891. The sensitivity was 93.33%, specificity was 75.86%, and accuracy was 87.64%. PFN1, ApoA-1, and SERPINA1 can serve as independent risk factors for predicting aneurysm rupture. The combined prediction of aneurysm rupture yielded an area under the ROC curve of 0.954 with a sensitivity of 96.15%, specificity of 81.48%, and accuracy of 88.68%. This prediction model was more effective than PHASES score. In conclusion, high-throughput proteomics analysis with population validation was performed to assess blood-based protein expression characteristics. This revealed the potential mechanism of IA formation and rupture, facilitating the discovery of biomarkers. Significance Although the annual rupture rate of small unruptured aneurysms is believed to be minimal, studies have indicated that ruptured aneurysms typically have an average size of 6.28 mm, with 71.8% of them being <7 mm in diameter. Hence, evaluating the possibility of rupture in UIA and making a choice between aggressive treatment and conservative observation emerges as a significant challenge in the management of UIA. No biomarker or scoring system has been able to satisfactorily address this issue to date. It would be significant to develop biomarkers that could be used for early diagnosis of IA as well as for prediction of IA rupture. After TMT proteomics analysis and ELISA validation in independent populations, we found that FN1, PON1, and SERPINA1 can be utilized as diagnostic biomarkers for IA, and PFN1, ApoA-1, and SERPINA1 can serve as independent risk factors for predicting aneurysm rupture. Especially, when combined with ApoA-1, SERPINA1, and PFN1 for predicting IA rupture, the area under the curve (AUC) was 0.954 with a sensitivity of 96.15%, specificity of 81.48%, and accuracy of 88.68%. This prediction model was more effective than PHASES score.

Plasma proteomics analysis reveals potential biomarkers for intracranial aneurysm formation and rupture

Mean Arterial Pressure-Aneurysm Neck Ratio Predicts the Rupture Risk of Intracranial Aneurysm by Reflecting Pressure at the Dome

Glypican-1 may be a plasma biomarker for predicting the rupture of small intracranial aneurysms.

Assessing Rupture Risk by Hemodynamics, Morphology and Plasma Concentrations of the Soluble Form of Tyrosine Kinase Receptor Axl in Unruptured Intracranial Aneurysms

Circulating Proteomic Panels for Risk Stratification of Intracranial Aneurysm and Its Rupture

Identification of the Soluble Form of Tyrosine Kinase Receptor Axl As a Potential Biomarker for Intracranial Aneurysm Rupture

Comprehensive Mass Spectrometry for Development of Proteomic Biomarkers of Intracranial Aneurysms.

Plasma Metabolic Signatures for Intracranial Aneurysm and Its Rupture Identified by Pseudotargeted Metabolomics.

Untargeted metabolomics to detect and identify plasma metabolic signatures associated with intracranial aneurysm and its rupture

Plasma metabolic signatures for intracranial aneurysm and its rupture identified by pseudotargeted metabolomics

Integrated Transcriptional Profiling Analysis and Immune-Related Risk Model Construction for Intracranial Aneurysm Rupture

Search for Biomarkers of Intracranial Aneurysms: A Systematic Review

Identifying and validating key genes mediating intracranial aneurysm rupture using weighted correlation network analysis and exploration of personalized treatment

Plasma levels of CD36 and glutathione as biomarkers for ruptured intracranial aneurysm

Increased Levels of Serum IL-15 and TNF-β Indicate the Progression of Human Intracranial Aneurysm

Identifying novel risk genes in intracranial aneurysm by integrating human proteomes and genetics

Expression Profile Analysis of Differentially Expressed Genes in Ruptured Intracranial Aneurysms: in Search of Biomarkers.

Featured Protein Analysis of Intracranial Aneurysms with Label-Free Quantitative Mass Spectrometry and Bioinformatics

Profiling of immune infiltration landscape of ruptured intracranial aneurysm

Circulating Micrornas Serve As Novel Biological Markers for Intracranial Aneurysms

Integrated metagenomic and metabolomic analysis reveals distinctive stage-specific gut-microbiome-derived metabolites in intracranial aneurysms